Abstract Number: 2415 • ACR Convergence 2024
Characterizing the Population with Suspected Lupus Nephritis in Care of a Community Rheumatology Network
Background/Purpose: Lupus nephritis (LN) has been estimated to develop in up to 40% of all patients with systemic lupus erythematosus (SLE), with higher rates in…Abstract Number: 2432 • ACR Convergence 2024
In Vitro and In Vivo Evidence of the Steroid-Sparing Potential of Afimetoran, an Equipotent Toll-Like Receptor 7/8 Dual Antagonist
Background/Purpose: SLE is a highly heterogeneous chronic autoimmune disease, with glucocorticoid therapy as the standard of care. SLE control requires high steroid doses; long-term use…Abstract Number: 2577 • ACR Convergence 2024
Efficacy and Safety of ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: Results Through 104 Weeks in a Long-Term Extension Study
Background/Purpose: ABBV-599 (a combination of a selective Bruton’s tyrosine kinase inhibitor, elsubrutinib [ELS], and a selective Janus kinase inhibitor, upadacitinib [UPA]) targets a spectrum of…Abstract Number: 2662 • ACR Convergence 2024
In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases
Background/Purpose: CAR T cell therapy promises to revolutionize the treatment of hematologic malignancies, and more recently has generated early data that it may afford long…Abstract Number: 0011 • ACR Convergence 2024
Preclinical Manufacturability and Activity of KYV-102 from Patients with Systemic Lupus Erythematosus Using Ingenui-T: A Rapid, Autologous Chimeric Antigen Receptor T-Cell Manufacturing Solution Utilizing Whole Blood
Background/Purpose: Apheresis in conventional chimeric antigen receptor (CAR) T-cell therapy can be burdensome, and conventional manufacturing cultures apheresis-derived cells for 7-14 days, leading to a…Abstract Number: 0109 • ACR Convergence 2024
Natural History and Clinical Implications of Lupus Autoantibodies in Primary Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Background/Purpose: Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are characterized by heterogenous clinical presentations, driven by autoantibodies; patients with SLE develop APS more often…Abstract Number: 0181 • ACR Convergence 2024
Integrated Multidisciplinary Lupus Social Work Program to Manage Social Determinants of Health in SLE and Lupus Nephritis – Preliminary Results
Background/Purpose: Minoritized individuals with systemic lupus erythematosus (SLE) experience social determinants of health (SDOH) challenges that affect access to care and increase the risk for…Abstract Number: 0212 • ACR Convergence 2024
Costs of Hospitalization in Patients with SLE: An Analysis of the National Inpatient Sample
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with significant health care utilization, medical costs, and increased risk of hospitalization. We aimed to characterize the reasons…Abstract Number: 0428 • ACR Convergence 2024
Placental Characteristics in Systemic Lupus Erythematosus Pregnancies Resulting in Small for Gestational Age Infants
Background/Purpose: About a quarter of pregnant individuals with systemic lupus erythematosus (SLE) have small for gestational age (SGA) infants. We aim to characterize placental pathology…Abstract Number: 0610 • ACR Convergence 2024
Clinical Evaluation on IFI44L Gene Methylation Detection for Diagnosis of Systemic Lupus Erythematosus by Methylation Sensitive High Resolution Melting (MS-HRM)
Background/Purpose: To evaluate the clinical effectiveness of IFI44L gene methylation detection for the diagnosis of Systemic Lupus Erythematosus (SLE) by MS-HRM, to determine the relative…Abstract Number: 0628 • ACR Convergence 2024
Genetic Determinants of Childhood Onset Systemic Lupus Erythematosus
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a multisystem autoimmune disease with significant morbidity and mortality. Genome-wide association studies have identified more than 100 variants…Abstract Number: 0647 • ACR Convergence 2024
Clinical Associations and Outcomes of Pericarditis in Systemic Lupus Erythematosus
Background/Purpose: Pericarditis is an important feature in the classification criteria and disease activity assessments in Systemic Lupus Erythematosus (SLE). We aimed to study the prevalence,…Abstract Number: 0665 • ACR Convergence 2024
Belimumab Induces Early and Sustained Resolution of Lupus Thrombocytopenia and Lupus Arthritis
Background/Purpose: Belimumab has well-established efficacy in improving overall SLE disease activity and in preventing flares and organ damage. In clinical routine, however, the primary goal…Abstract Number: 0815 • ACR Convergence 2024
Interferon-stimulated Gene Expression in Non-lesional Skin Is Similarly Elevated in Incomplete SLE and SLE
Background/Purpose: Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria are referred to as incomplete SLE (ILE). These patients are…Abstract Number: 0986 • ACR Convergence 2024
State-and-County-Level Social Vulnerability Index and Trends in Systemic Lupus Erythematosus-Related Mortality in the U.S
Background/Purpose: Epidemiological studies have shown significant health disparities in systemic lupus erythematosus (SLE). The Centers for Disease Control and Prevention (CDC) developed the social vulnerability…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 150
- Next Page »